NYSE:TAROTaro Pharmaceutical Industries Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Taro Pharmaceutical Industries Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $65.63 +0.50 (+0.77 %) (As of 07/13/2020 04:00 PM ET) Add Compare Share Today's Range$65.53Now: $65.63▼$66.7250-Day Range$64.21MA: $67.29▼$69.0852-Week Range$56.07Now: $65.63▼$99.69Volume793 shsAverage Volume26,962 shsMarket Capitalization$2.51 billionP/E Ratio10.32Dividend YieldN/ABeta0.79 ProfileAnalyst RatingsAdvanced ChartCompetitorsDividendEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Zrt.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingTaro Pharmaceutical Industries has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $96.00, Taro Pharmaceutical Industries has a potential upside of 46.3% from its current price of $65.63.Amount of Analyst CoverageTaro Pharmaceutical Industries has only been the subject of 1 research reports in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesTaro Pharmaceutical Industries has received 248 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTaro Pharmaceutical Industries has received 309 “underperform” votes. (Add your “underperform” vote.)Community SentimentTaro Pharmaceutical Industries has received 55.48% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Taro Pharmaceutical Industries and other stocks. Vote “Outperform” if you believe TARO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TARO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTaro Pharmaceutical Industries does not currently pay a dividend.Dividend GrowthTaro Pharmaceutical Industries does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Taro Pharmaceutical Industries insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 13.80% of the stock of Taro Pharmaceutical Industries is held by insiders.Percentage Held by InstitutionsOnly 11.60% of the stock of Taro Pharmaceutical Industries is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Taro Pharmaceutical Industries are expected to decrease by -100.00% in the coming year, from $6.55 to $0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Taro Pharmaceutical Industries is 10.32, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 16.84.Price to Earnings Ratio vs. SectorThe P/E ratio of Taro Pharmaceutical Industries is 10.32, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.37.Price to Book Value per Share RatioTaro Pharmaceutical Industries has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.39 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:TARO Previous Symbol CUSIPN/A CIK906338 Webwww.taro.com Phone914-345-9000Debt Debt-to-Equity RatioN/A Current Ratio6.88 Quick Ratio6.19Price-To-Earnings Trailing P/E Ratio10.32 Forward P/E Ratio10.02 P/E GrowthN/A Sales & Book Value Annual Sales$644.77 million Price / Sales3.89 Cash Flow$7.00 per share Price / Cash Flow9.38 Book Value$55.15 per share Price / Book1.19Profitability EPS (Most Recent Fiscal Year)$6.35 Net Income$244.24 million Net Margins37.88% Return on Equity11.94% Return on Assets10.79%Miscellaneous Employees1,464 Outstanding Shares38,260,000Market Cap$2.51 billion Next Earnings Date8/13/2020 (Estimated) OptionableOptionable TARO Rates by TradingView Receive TARO News and Ratings via Email Sign-up to receive the latest news and ratings for TARO and its competitors with MarketBeat's FREE daily newsletter. Taro Pharmaceutical Industries (NYSE:TARO) Frequently Asked Questions How has Taro Pharmaceutical Industries' stock been impacted by COVID-19 (Coronavirus)? Taro Pharmaceutical Industries' stock was trading at $64.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TARO stock has increased by 1.8% and is now trading at $65.63. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Taro Pharmaceutical Industries? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Taro Pharmaceutical Industries. When is Taro Pharmaceutical Industries' next earnings date? Taro Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Taro Pharmaceutical Industries. How were Taro Pharmaceutical Industries' earnings last quarter? Taro Pharmaceutical Industries Ltd. (NYSE:TARO) issued its earnings results on Tuesday, May, 19th. The company reported $1.42 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.53 by $0.11. The company earned $174.94 million during the quarter, compared to the consensus estimate of $168.25 million. Taro Pharmaceutical Industries had a return on equity of 11.94% and a net margin of 37.88%. View Taro Pharmaceutical Industries' earnings history. What price target have analysts set for TARO? 1 brokerages have issued 12-month target prices for Taro Pharmaceutical Industries' shares. Their forecasts range from $96.00 to $96.00. On average, they anticipate Taro Pharmaceutical Industries' share price to reach $96.00 in the next twelve months. This suggests a possible upside of 46.3% from the stock's current price. View analysts' price targets for Taro Pharmaceutical Industries. Has Taro Pharmaceutical Industries been receiving favorable news coverage? News headlines about TARO stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Taro Pharmaceutical Industries earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Taro Pharmaceutical Industries. Are investors shorting Taro Pharmaceutical Industries? Taro Pharmaceutical Industries saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 133,500 shares, a decline of 7.4% from the June 15th total of 144,200 shares. Based on an average trading volume of 35,300 shares, the days-to-cover ratio is presently 3.8 days. Currently, 1.5% of the shares of the stock are short sold. View Taro Pharmaceutical Industries' Current Options Chain. Who are some of Taro Pharmaceutical Industries' key competitors? Some companies that are related to Taro Pharmaceutical Industries include Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), ACADIA Pharmaceuticals (ACAD), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Mylan (MYL), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), PPD (SDGR), United Therapeutics (UTHR), Ultragenyx Pharmaceutical (RARE), Reata Pharmaceuticals (RETA) and Zai Lab (ZLAB). View all competitors. What other stocks do shareholders of Taro Pharmaceutical Industries own? Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Broadcom (AVGO), Bausch Health Companies (BHC), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals PLC- (GWPH), Jazz Pharmaceuticals (JAZZ), Mallinckrodt (MNK) and Novo Nordisk A/S (NVO). Who are Taro Pharmaceutical Industries' key executives? Taro Pharmaceutical Industries' management team includes the following people: Mr. Uday V. Baldota, CEO & Director (Age 49)Mr. Mariano Balaguer, CFO, Chief Accounting Officer & VP (Age 46)Mr. Itamar Karsenti, VP & Head of Global Operations (Age 47)Mr. Itzik Baruch, VP of Technical Services (Age 56)Dr. Roman Kaplan Ph.D., VP of Scientific and Technical Compliance Mang. (Age 72) What is Taro Pharmaceutical Industries' stock symbol? Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO." How do I buy shares of Taro Pharmaceutical Industries? Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Taro Pharmaceutical Industries' stock price today? One share of TARO stock can currently be purchased for approximately $65.63. How big of a company is Taro Pharmaceutical Industries? Taro Pharmaceutical Industries has a market capitalization of $2.51 billion and generates $644.77 million in revenue each year. The company earns $244.24 million in net income (profit) each year or $6.35 on an earnings per share basis. Taro Pharmaceutical Industries employs 1,464 workers across the globe. What is Taro Pharmaceutical Industries' official website? The official website for Taro Pharmaceutical Industries is www.taro.com. How can I contact Taro Pharmaceutical Industries? Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 914-345-9000 or via email at [email protected] This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
